These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 32602890)

  • 21. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
    Eapen RS; Herlemann A; Washington SL; Cooperberg MR
    Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer: Draft USPSTF 2017 recommendation on PSA testing - a sea-change?
    Van der Kwast TH; Roobol MJ
    Nat Rev Urol; 2017 Aug; 14(8):457-458. PubMed ID: 28607501
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations.
    Sammon JD; Abdollah F; Choueiri TK; Kantoff PW; Nguyen PL; Menon M; Trinh QD
    JAMA; 2015 Nov; 314(19):2077-9. PubMed ID: 26575066
    [No Abstract]   [Full Text] [Related]  

  • 24. PURL: USPSTF expands options for cervical cancer screening.
    Oyola S; VanGompel EW
    J Fam Pract; 2020; 69(6):E7-E9. PubMed ID: 32724915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty.
    Ng K; May FP; Schrag D
    JAMA; 2021 May; 325(19):1943-1945. PubMed ID: 34003238
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.
    Fleshner K; Carlsson SV; Roobol MJ
    Nat Rev Urol; 2017 Jan; 14(1):26-37. PubMed ID: 27995937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What's new in screening in 2015?
    Carlsson SV; Roobol MJ
    Curr Opin Urol; 2016 Sep; 26(5):447-58. PubMed ID: 27326657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAMA Forum: Lung cancer screening and evidence-based policy.
    Bindman A
    JAMA; 2015 Jan; 313(1):17-8. PubMed ID: 25562251
    [No Abstract]   [Full Text] [Related]  

  • 29. Reanalysis of All-Cause Mortality in the U.S. Preventive Services Task Force 2016 Evidence Report on Colorectal Cancer Screening.
    Swartz AW; Eberth JM; Josey MJ; Strayer SM
    Ann Intern Med; 2017 Oct; 167(8):602-603. PubMed ID: 28828493
    [No Abstract]   [Full Text] [Related]  

  • 30. America, We Are Confused: The Updated U.S. Preventive Services Task Force Recommendation on Colorectal Cancer Screening.
    Bretthauer M; Kaminski MF; Hassan C; Kalager M; Holme Ø; Hoff G; Løberg M; Regula J; Castells A; Adami HO
    Ann Intern Med; 2017 Jan; 166(2):139-140. PubMed ID: 27820949
    [No Abstract]   [Full Text] [Related]  

  • 31. USPSTF says no screening for ovarian cancer in new guidelines.
    Oncology (Williston Park); 2012 Oct; 26(10):896, 928. PubMed ID: 23175994
    [No Abstract]   [Full Text] [Related]  

  • 32. Margaret McCartney: Why ask, if you ignore the answer?
    McCartney M
    BMJ; 2017 Apr; 357():j1824. PubMed ID: 28420640
    [No Abstract]   [Full Text] [Related]  

  • 33. Preventing Lung Cancer Mortality by Computed Tomography Screening: The Effect of Risk-Based Versus U.S. Preventive Services Task Force Eligibility Criteria, 2005-2015.
    Cheung LC; Katki HA; Chaturvedi AK; Jemal A; Berg CD
    Ann Intern Med; 2018 Feb; 168(3):229-232. PubMed ID: 29297008
    [No Abstract]   [Full Text] [Related]  

  • 34. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.
    Schröder FH
    N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756
    [No Abstract]   [Full Text] [Related]  

  • 35. Task force recommends targeted lung cancer screening.
    Friedrich MJ
    JAMA; 2013 Sep; 310(9):892-3. PubMed ID: 24002258
    [No Abstract]   [Full Text] [Related]  

  • 36. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
    Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
    Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening mammography and the "r" word.
    Truog RD
    N Engl J Med; 2009 Dec; 361(26):2501-3. PubMed ID: 19940292
    [No Abstract]   [Full Text] [Related]  

  • 38. Prostate cancer screening--the evidence, the recommendations, and the clinical implications.
    Chou R; LeFevre ML
    JAMA; 2011 Dec; 306(24):2721-2. PubMed ID: 22203543
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.
    Brett AS; Ablin RJ
    N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759
    [No Abstract]   [Full Text] [Related]  

  • 40. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline.
    Peterse EFP; Meester RGS; Siegel RL; Chen JC; Dwyer A; Ahnen DJ; Smith RA; Zauber AG; Lansdorp-Vogelaar I
    Cancer; 2018 Jul; 124(14):2964-2973. PubMed ID: 29846933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.